“South Africa is at the forefront of HIV prevention innovation, with Aspen Pharmacare licensed to produce a new once‑a‑month pill, alimatravir, even before trials conclude. This strategy, combined with the rollout of six‑monthly injections, could transform prevention by offering people more flexible options.”
South Africa, home to one of the world’s largest HIV epidemics, is witnessing a pivotal moment in its fight against the virus. A new once‑a‑month HIV prevention pill, alimatravir (MK‑8527), developed by Merck (MSD in South Africa), is entering late‑stage trials. In a groundbreaking move, Merck has already granted licences to seven generic manufacturers, including Aspen Pharmacare, South Africa’s largest drug maker, to prepare production before regulatory approval.
Why This Matters
- 140,000 new HIV infections annually in South Africa highlight the urgent need for scalable prevention.
- Current options include daily oral pills and the six‑monthly injection lenacapavir (LEN), rolled out in June 2026.
- Uptake data shows 98.5% of HIV‑negative patients offered LEN chose it over daily pills, proving that convenience drives adoption.
The Innovation: Alimatravir
- Monthly dosage balances convenience with adherence.
- Licensing before trial completion is unprecedented, allowing factories to prepare early.
- Aspen Pharmacare’s role: importing the active ingredient, assembling the pill locally, and distributing across 129 low‑ and middle‑income countries.
Economic and Industrial Impact
- Cost estimate: $4.50 (R76) per person per year, far cheaper than LEN.
- Boost for African pharmaceutical industrialisation: Aspen’s licence strengthens regional manufacturing ambitions.
- Export potential: all 54 African countries included in Aspen’s distribution rights.
Uptake and Accessibility
- Choice matters: daily pill, monthly pill, or six‑monthly jab.
- LEN rollout data: 31,297 South Africans already using LEN, representing over half of Africa’s users.
- Provincial concentration: Gauteng and KwaZulu‑Natal lead uptake due to clinic availability.
Risks and Challenges
- Uncertainty: alimatravir’s effectiveness is still under trial.
- Volume requirement: tens of millions of doses needed to sustain low pricing.
- Regulatory hurdles: phase 3 trials across 17 countries must conclude successfully by 2027.
Voices from the Field
- Mitchell Warren (Avac): “It’s a risk, but a wise one.”
- Stavros Nicolaou (Aspen): “This is a significant boost for Africa’s pharmaceutical ambitions.”
Broader Implications
- Public health: expanding prevention choices could reduce stigma and improve adherence.
- Global equity: licensing African manufacturers early ensures faster access for low‑income countries.
- Strategic positioning: South Africa cements its role as a leader in HIV prevention innovation.
Conclusion
South Africa’s dual rollout of LEN and preparation for alimatravir marks a turning point in HIV prevention. By prioritising choice, affordability, and local manufacturing, the country is not only addressing its own epidemic but also shaping the future of HIV prevention across Africa.
